Anderly C. Chueh
Affiliations: | The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia |
Area:
Epigenetic Enzymes, Mitotic Signaling, Translational Cancer Biology, Drug Development, Biomarker IdentificationGoogle:
"Anderly Chueh"Mean distance: (not calculated yet)
Parents
Sign in to add mentorKH Andy Choo | grad student | 2003-2008 | University of Melbourne |
Lee H. Wong | grad student | 2003-2008 | |
John M. Mariadason | post-doc | 2009-2013 | Ludwig Institute for Cancer Research |
Ian P. Street | research scientist | 2016- | Walter and Eliza Hall Institute of Medical Research |
Antony W. Burgess | research scientist | 2014-2016 | Walter and Eliza Hall Institute of Medical Research |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Chüeh AC, Tse JWT, Dickinson M, et al. (2023) Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 3826 |
Sharma S, Chung CY, Uryu S, et al. (2023) Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chemical Biology |
Tögel L, Nightingale R, Wu R, et al. (2023) Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 13: 2422 |
Chionh F, Gebski V, Al-Obaidi SJ, et al. (2022) VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports. 12: 1238 |
Chüeh AC, Advani G, Foroutan M, et al. (2021) CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. Oncogene |
Grohmann C, Walker F, Devlin M, et al. (2021) Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death & Disease. 12: 268 |
Tögel L, Nightingale R, Wu R, et al. (2018) DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 8: 1767 |
Chüeh AC, Liew MS, Russell PA, et al. (2017) Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget. 8: 74036-74048 |
Chüeh AC, Tse JW, Dickinson M, et al. (2017) ATF3 repression of BCL-XL determines apoptotic sensitivity toHDAC inhibitors across tumour types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Tögel L, Nightingale R, Chueh AC, et al. (2016) Dual targeting of bromodomain and extra-terminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells. Molecular Cancer Therapeutics |